Type of non Hodgkin's lymphoma-Mantle cell lymphoma Page 2 Posts on Medivizor
Navigation Menu

Type of non Hodgkin’s lymphoma-Mantle cell lymphoma Posts on Medivizor

The impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned stem cell transplant

Posted by on Mar 26, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the impact of the graft-versus-lymphoma effect on the outcomes for patients with lymphoma who are treated with reduced-intensity conditioning (RIC) with alemtuzumab (Lemtrada) allogeneic hematopoietic stem cell transplant (allo-HSCT).  This study concluded that the graft-versus-lymphoma effect leads to...

Read More

Searching for patients to try a new therapy for non-responsive lymphoma after stem-cell transplant.

Posted by on Mar 15, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study will investigate the effects of ibrutinib (Imbruvica) in patients with non-responsive lymphoma after a stem-cell transplant. The main outcome that will be measured is the time after treatment before patients experience cancer worsening. This trial is recruiting in the United States. The details Some patients with lymphoma lose...

Read More

Combining ibrutinib and umbralisib to treat relapsed/unresponsive mantle cell lymphoma

Posted by on Feb 28, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of ibrutinib (Imbruvica) combined with umbralisib for patients with released/unresponsive mantle cell lymphoma (MCL). This study concluded that the combination of umbralisib and ibrutinib is well tolerated and effective in these patients.  Some background Mantle cell...

Read More

Looking for patients with relapsed or unresponsive mantle cell lymphoma to test a new treatment

Posted by on Feb 28, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This phase 2 trial is evaluating the safety and effectiveness of a new targeted therapy for relapsed or unresponsive mantle cell lymphoma (MCL). The main outcome to be measured is the overall response rate to treatment. The details Ibrutinib (Imbruvica) is a commonly used therapy for patients with relapsed or refractory MCL. This...

Read More

Evaluating the impact of quality of life at diagnosis on patient outcomes for aggressive lymphoma

Posted by on Feb 9, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated whether quality of life (QOL) scores impact outcomes for patients with aggressive lymphoma. This study concluded that QOL scores at diagnosis may predict survival outcomes for these patients. Some background The International Prognostic Index (IPI) is the most widely used tool to predict survival outcomes for...

Read More

Predicting the effects of stem cell transplant in older patients with non-Hodgkin lymphoma.

Posted by on Feb 9, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effects of stem cell transplant for non-Hodgkin lymphoma (NHL) in older patients. The main finding was that patients who responded to chemotherapy had better outcomes after stem cell transplant. Some background Stem cell transplant is often used to treat NHL. This involves the transfer of healthy cells to a...

Read More

Evaluating front-line allogeneic stem cell transplantation for mantle cell lymphoma

Posted by on Jan 12, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the outcomes of patients with mantle cell lymphoma (MCL) after front-line (primary) allogeneic stem cell transplantation (alloSCT). This study concluded that front-line alloSCT is effective in these patients. Some background Chemoimmunotherapy containing rituximab (Rituxan) is the typical front-line...

Read More

Evaluating the impact of autoimmune conditions on the outcomes of patients with lymphoma

Posted by on Dec 13, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the impact of autoimmune conditions on the outcomes of patients with lymphoma. This study concluded that these conditions may negatively impact survival outcomes for these patients. Some background Autoimmune conditions are a group of diseases where the immune system attacks the body’s healthy tissues. One...

Read More

Evaluating the VR-CAP regimen versus R-CHOP in transplant-ineligible patients with mantle cell lymphoma

Posted by on Nov 10, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of first-line (primary) treatment with VR-CAP (bortezomib, rituximab, cyclophosphamide, doxorubicin, prednisone) versus R-CHOP (VR-CAP with vincristine instead of bortezomib) alone in previously untreated patients with mantle cell lymphoma (MCL). This study concluded that VR-CAP was...

Read More

Serious infections in patients receiving ibrutinib for the treatment of leukemia and lymphoma

Posted by on Sep 27, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the risk of infections associated with ibrutinib (Imbruvica) used in the treatment of leukemia and lymphoma. Researchers found that patients receiving ibrutinib are at risk of serious infections. Some background Ibrutinib is a drug which targets certain proteins on cancer cells to stop them from working. It is often...

Read More